


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

(51) International Patent Classification 7 : A61K 31/19, A61P 35/00, 35/02, 37/06, A61K 35/78		A1	(11) International Publication Number: WO 00/66111
			(43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/US00/08217		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 28 April 2000 (28.04.00)			
(30) Priority Data: 09/302,510 30 April 1999 (30.04.99) US			
(71) Applicant (for all designated States except US): SABINSA CORPORATION [US/US]; 121 Ethel Road West, Unit 6, Piscataway, NJ 08854 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MAJEED, Muhammed [US/US]; 121 Ethel Road West, Unit 6, Piscataway, NJ 08854 (US). BADMAEV, Vladimir [US/US]; 121 Ethel Road West, Unit 6, Piscataway, NJ 08854 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(74) Agents: MURRAY, Robert, B. et al.; Arent Fox Kintner Plotkin & Kahn, PLLC, Suite 600, 1050 Connecticut Avenue, N.W., Washington, DC 20036-5339 (US).			

(57) Abstract

Method of treatment of lymphoproliferative and autoimmune disorders with a new composition of four boswellic acids including β -boswellic acid, 3-O-acetyl- β -boswellic acid, 11-keto- β -boswellic acid, and 3-O-acetyl-11-keto- β -boswellic acid. Boswellic acids of invention have been obtained in a novel industrial process from the gum resin of *Boswellia serrata* tree, providing standardized composition which inhibits DNA, RNA and protein synthesis of the target cell without cytotoxic effects. Composition of invention provides advantage of irreversible cytostatic therapy, equivalent to biological effects of a cytotoxic therapy without killing body cells.



Inhibitory effect of compound 4 on the growth of HL-60 cells. Results represent the average values for three experiments each performed in triplicate. Significantly different from control, $P < 0.05$.